Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.
Siriratnam P, Sanfilippo P, van der Walt A, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Yamout B, Laureys G, Patti F, Simo M, Surcinelli A, Foschi M, McCombe PA, Alroughani R, Sánchez-Menoyo JL, Turkoglu R, Soysal A, Lechner Scott J, Kalincik T, Butzkueven H, Jokubaitis V, Huda S, Monif M; MSBASE study group. Siriratnam P, et al. Among authors: willekens b. J Neurol Neurosurg Psychiatry. 2024 Sep 4:jnnp-2024-334090. doi: 10.1136/jnnp-2024-334090. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39231582
Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR, Levy M, Weinshenker BG, Banwell BL, Fujihara K, Abboud H, Dujmovic Basuroski I, Arrambide G, Neubrand VE, Quan C, Melamed E, Palace J, Sun J, Asgari N, Broadley SA; Guthy Jackson International Clinical Consortium*. Arnett S, et al. J Neurol. 2024 Aug;271(8):4794-4812. doi: 10.1007/s00415-024-12452-8. Epub 2024 Jul 3. J Neurol. 2024. PMID: 38958756 Free PMC article. Review.
The European Academy of Neurology NeuroCOVID-19 Task Force: A lesson for the future.
Cavallieri F, Sellner J, Akhvlediani T, Bassetti CL, Bereczki D, Fanciulli A, Filipović SR, Guekht A, Helbok R, Hochmeister S, Martinelli Boneschi F, von Oertzen TJ, Özturk S, Priori A, Ramankulov D, Willekens B, Rakusa M, Moro E; NeuroCOVID‐19 Task Force of the European Academy of Neurology. Cavallieri F, et al. Among authors: willekens b. Eur J Neurol. 2025 Jan;32(1):e16321. doi: 10.1111/ene.16321. Epub 2024 Apr 26. Eur J Neurol. 2025. PMID: 38676302 Free PMC article.
The COVID-19 pandemic and neurology: A survey on previous and continued restrictions for clinical practice, curricular training, and health economics.
Rakusa M, Moro E, Akhvlediani T, Bereczki D, Bodini B, Cavallieri F, Fanciulli A, Filipović SR, Guekht A, Helbok R, Hochmeister S, Martinelli Boneschi F, Özturk S, Priori A, Romoli M, Willekens B, Zedde M, Sellner J; NeuroCOVID-19 Task Force of the European Academy of Neurology. Rakusa M, et al. Among authors: willekens b. Eur J Neurol. 2024 Mar;31(3):e16168. doi: 10.1111/ene.16168. Epub 2023 Dec 1. Eur J Neurol. 2024. PMID: 38038262 Free PMC article.
Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers - An updated European Academy of Neurology consensus statement.
Filipović SR, Özturk S, Bereczki D, Bodini B, Cavallieri F, Fanciulli A, Guekht A, Helbok R, Hochmeister S, Martinelli Boneschi F, Priori A, Rakusa M, Romoli M, Willekens B, Zedde M, Sellner J, Moro E; Neuro COVID‐19 Task Force of the European Academy of Neurology. Filipović SR, et al. Among authors: willekens b. Eur J Neurol. 2024 Oct;31(10):e16408. doi: 10.1111/ene.16408. Epub 2024 Aug 1. Eur J Neurol. 2024. PMID: 39088330 Free PMC article.
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT.
Muraro PA, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, Snowden JA, Alexander T, Amato MP, Bø L, Boffa G, Ciccarelli O, Cohen JA, Derfuss T, Farge D, Freedman MS, Gaughan M, Heesen C, Kazmi M, Kirzigov K, Ljungman P, Mancardi G, Martin R, Mehra V, Moiola L, Saccardi R, Tintoré M, Stankoff B, Sharrack B; Attendees of the ECTRIMS Focused Workshop on HSCT. Muraro PA, et al. Nat Rev Neurol. 2025 Jan 15. doi: 10.1038/s41582-024-01050-x. Online ahead of print. Nat Rev Neurol. 2025. PMID: 39814869 Review.
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
Siriratnam P, Huda S, Van Der Walt A, Sanfilippo PG, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello CM, Laureys G, Patti F, Horakova D, Foschi M, Boz C, Mccombe PA, Turkoglu R, Lechner-Scott J, Roos I, Kalincik T, Jokubaitis VG, Butzkueven H, Monif M; for MSBase. Siriratnam P, et al. Among authors: willekens b. Neurology. 2024 Dec 24;103(12):e209940. doi: 10.1212/WNL.0000000000209940. Epub 2024 Nov 19. Neurology. 2024. PMID: 39561307
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study.
Levitz D, Chao Foong Y, Sanfilippo P, Spelman T, Rath L, Roldan A, Lal A, Monif M, Jokubaitis V, Ozakbas S, Alroughani R, Boz C, Terzi M, Kalincik T, Blanco Y, Foschi M, Surcinelli A, Buzzard K, Skibina O, Laureys G, Van Hijfte L, Ramo-Tello C, Soysal A, Sanchez-Menoyo JL, Habek M, Cartechini E, Rojas JI, Karabudak R, Willekens B, Al-Harbi T, Fragoso Y, Castillo-Triviño T, Decoo D, Aragon de Vecino MC, Skromne E, Sirbu CA, Zhu C, Merlo D, Gresle M, Butzkueven H, Van Der Walt A. Levitz D, et al. Among authors: willekens b. Ther Adv Neurol Disord. 2024 Nov 7;17:17562864241278496. doi: 10.1177/17562864241278496. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39525878 Free PMC article.
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabis-Pedrini MJ, Carroll WM, Lechner-Scott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, Van Pesch V, Laureys G, Willekens B, Prevost J, Foschi M, De Gans K, Horakova D, Havrdova EK, Karabudak R, Patti F, Mccombe PA, Maimone D, Altintas A, Ampapa R, Spitaleri D, Gerlach OHH, Sa MJ, Hughes S, Gouider R, Mrabet S, Macdonell RA, Turkoglu R, Cartechini E, Al-Asmi A, Soysal A, Oh J, Muros-Le Rouzic E, Guye S, Pasquarelli N, Butzkueven H, Jokubaitis VG; MSBase Study Group. Yeh WZ, et al. Among authors: willekens b. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200328. doi: 10.1212/NXI.0000000000200328. Epub 2024 Oct 23. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39442037 Free PMC article.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
122 results